Coxidin® 90 — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Coxidin® 90

Active ingredient

Monensin

Application type

ANADA

Sponsor

Huvepharma EOOD

Applications on record

1

First published

September 3, 2024

Adverse event reports

Source: openFDA VeDDRA

2,206

Reports mentioning this ingredient

January 26, 1987 – March 25, 2026

28

Classified serious

per reporter assessment

295

Lack of expected efficacy

resistance signal

433

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “MONENSIN”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Death	1,109
Anorexia	468
Accidental exposure	433
Diarrhoea	354
Inappropriate preparation of medication	315
Lack of efficacy (protozoa) - Coccidia	280
Recumbency	200
Alteration of milk quality	170
PR-HEART, LESION(S)	142
Depression	132
Milk production decrease	126
Ataxia	88
Ruminal bloat	85
UNPALATABLE	73
Loose stool	67
TOXICITY	60
Bloody diarrhoea	60
Weakness	56
Dyspnoea	53
Death by euthanasia	51

Species affected

Source: openFDA VeDDRA

Cattle 1,399 Turkey 204 Horse 186 Chicken 96 Sheep 75 Dog 49 Goat 40 Human 28 Pig 18 Other 15 Other Birds 9 Alpaca 6

Regulatory context

Abbreviated New Animal Drug Application (ANADA). A generic animal drug demonstrating bioequivalence, pharmaceutical equivalence and identical manufacturing criteria to the pioneer application. Veterinary generics have no formal therapeutic-equivalence coding system; they match the pioneer NADA specification instead.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient